Skip to content

To study the role of febuxostat in decreasing adverse effects of free radicals in cardiac surgery

Pre-operative use of Febuxostat in cardiac surgery- a double blind prospective ramdomized phase II trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030807
Enrollment
200
Registered
2021-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I00-I99- Diseases of the circulatory system

Interventions

Intervention1: Febuxostat: 80mg dose to be given preoperatively at 12 hours and 2 hours prior surgery Control Intervention1: Placebo: one dose to be given 12 hours and 2 hours before surgery

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: As per parameters defined above all adult patients undergoing cardiac surgery under with overall EUROSCORE II Specific parameters: - - Age 18- 65 - Elective and Urgent procedure - Weight of procedure – 1. Isolated CABG 2. Isolated non-CABG major procedure (e.g. single valve procedure, replacement of ascending aorta, correction of septal defect, etc) 3. 2 major procedures (e.g. CABG and AVR), or CABG and mitral valve repair (MVR), or AVR and replacement of ascending aorta, or CABG and maze procedure, or AVR and MVR, etc

Exclusion criteria

Exclusion criteria: 1 Cyanotic heart disease 2 Off pump procedure, DHCA 3 Emergency and salvage procedures 4 =3 major procedures (e.g. AVR, MVR, and CABG, or MVR, CABG, and tricuspid annuloplasty, etc), or aortic root replacement when it includes AVR or repair, coronary reimplantation, and root and ascending replacement 5 Severe renal dysfunction - =50 mL/min - On dialysis (regardless of serum creatinine) 6 NYHA Class IV: symptoms at rest 7 Poor (LVEF 21-30%), Very poor (LVEF =20%) 8 Active infection

Design outcomes

Primary

MeasureTime frame
To compare the attenuation of myocardial ischemic-reperfusion injury between adult patients undergoing cardiac surgery, given febuxostat preoperatively (interventional arm) and placebo preoperatively ( non-interventional arm) Timepoint: 24 hours

Secondary

MeasureTime frame
To assess attenuation of cardiac injury markers and inflammatory markersTimepoint: 24 hours;To assess presence of Low cardiac output syndrome by inotrope score and clinicallyTimepoint: 24 hours;To assess rhythm disturbance if anyTimepoint: 24 hours

Countries

India

Contacts

Public ContactTanushree kar

AIIMS

vdeva@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026